Prevention

Authors of a report released by the Institute of Medicine (IOM) on sodium intake by the American public failed to be persuaded that lowering daily consumption below 2,300 mg a day affected outcomes. The American Heart Association (AHA) countered the report missed the mark in its conclusions.

Prevention

Ranbaxy pays $500M to settle adulterated drugs suit

Ranbaxy has agreed to pay $500 million to settle a whistleblower lawsuit that claimed the pharmaceutical manufacturer made and distributed adulterated drugs at two facilities in India. The payment includes $350 million as a civil settlement plus $150 million in criminal fines.

Prevention

Statins may lower risk of death from prostate cancer

Statin users diagnosed with prostate cancer were less likely to die from the disease compared with nonstatin users, according to results of a prospective, population-based study published online May 1 in The Prostate.

Prevention

Persistence pays off: FDA OKs Merck’s combo drug

The FDA approved the combo tablet ezetimibe and atorvastatin for the treatment of elevated levels of low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia.

Prevention

FDA links illegal DMAA to MI, arrhythmias

The FDA took aim at DMAA again, warning that the amphetamine derivative poses cardiovascular risks, including the potential for arrhythmias and MI. “Dietary supplements containing DMAA are illegal and FDA is doing everything within its authority to remove these products from the market,” according to the agency.

Prevention

Previous Pause Next

How one family may help break code in heart disease

Preparing for the worst

AMA steps up efforts to control hypertension

Chelation therapy: Focus on findings

Osteoporosis drug under review for cardiac risks

Ex-CDC director’s focus on the positive

Canadian diabetes guidelines: Start statins at 40

Chip to chubbiness: Resistance is futile

Research gets to the meat of the matter

More reported hypertension: A sign of progress?